Navigation Links
Questcor to Report First Quarter Results on April 30, 2013

ANAHEIM, Calif., April 15, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced that it will release first quarter 2013 financial results on Tuesday, April 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, April 30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website,
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 34200996.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Fourth Quarter and Full Year 2012 Results
2. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
3. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
4. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
6. Questcor to Conduct Conference Call to Discuss Reimbursement Process
7. Questcor Comments on Insurance Policy Bulletin
8. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
9. Questcor Pharmaceuticals to Present at Investor Conferences in September
10. Questcor Reports Second Quarter Financial Results
11. Questcor to Report Second Quarter Results on July 24, 2012
Post Your Comments:
(Date:11/30/2015)... and BASEL, Switzerland , Dec. ... (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd., ... of a novel, oral small molecule inhibitor of Vascular ... be effective in the treatment of inflammatory disease. The ... --> --> Under ...
(Date:11/30/2015)... -- Researchers have developed software for the Microsoft Kinect ... for motion, positioning and beam adjustment immediately before X-ray ... the annual meeting of the Radiological Society of ... Don , M.D., associate professor of radiology at Mallinckrodt ... St. Louis, Mo. "This technology ...
(Date:11/30/2015)... , Dec. 1, 2015 Express Scripts (NASDAQ: ... (NASDAQ: IMMY ) to drive access to a low-cost ... treatment of toxoplasmosis that has been recently priced out of ... weakened immune systems. --> --> ... and leucovorin (a form of folic acid) for $1 per capsule ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... engine optimization companies, announced today that it has officially launched a sleek, mobile-ready ... SEO, explained that his company’s new website clearly outlines the benefits that its ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Beard and Brooke Bennett are collaborating with brands across various categories through traditional ... influential figures make up an elite group of Gold Medal Moms who can ...
(Date:11/30/2015)... Cary, NC (PRWEB) , ... November 30, 2015 , ... ... and corporate support as they play for the chance to represent the United States. ... fans the opportunity to be a part of their journey in addition to offering ...
(Date:11/30/2015)... ... December 01, 2015 , ... The Turks & Caicos Islands has ... leading digital news sites highlighting Caribbean destinations, has published five reasons to visit the ... North America shivers under chilly grey skies or worse, it's typically a balmy 80 ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting 850,000 members and over 200 operating Local ...
Breaking Medicine News(10 mins):